The first participant has been dosed in an investigator-initiated Phase 2 clinical trial testing Neuraly‘s experimental medication pegsebrenatide as a potential treatment for progressive forms of multiple sclerosis (MS). Called TAG-MS (NCT07497399), the study is being led by Ellen Mowry, MD, at Johns Hopkins University in Maryland, with additional clinical sites expected to participate. The […]
The post Phase 2 pegsebrenatide trial begins dosing in progressive MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com